It is approved by numerous regulatory administrations worldwide, including the US Food and Drug Administration (FDA) (19 October 2009), the European Union's European Medicines Agency (EMA) (14 June 2010), the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) (14 June 2010) and Australia's Therapeutic Goods Administration (TGA) (30 June 2010), for use as a treatment for advanced/metastatic renal cell carcinoma and advanced soft tissue sarcomas. In Australia and New Zealand, it is subsidised under the Pharmaceutical Benefits Scheme (PBS) and by Pharmac respectively, under a number of conditions, including: * The medication is used to treat clear cell renal cell carcinoma, the most common histological subtype. * The treatment phase is continuing treatment beyond 3 months. * The patient has been issued an authority prescription for<unk> . * The patient must have stable or responding disease according to the Response Evaluation Criteria In Solid Tumours (RECIST). * This treatment must be the sole tyrosine kinase inhibitor subsidised for this condition.<unk>  has also demonstrated initial therapeutic properties in patients with ovarian and non-small cell lung cancer, though plans to apply to the EMA for a variation to include advanced ovarian cancer have been withdrawn and a license will not be sought in any country.
Pazopanib
Vatalanib
Pegaptanib
Tivozanib
Nintedanib
Abrocitinib
Gilteritinib
Erdafitinib